Resistant Hypertension in Dialysis: Epidemiology, Diagnosis, and Management

• Published in: Journal of the American Society of Nephrology Vol. 35; no. 4; p. 505
• Main Authors: Georgianos, Panagiotis I, Agarwal, Rajiv
• Format: Journal Article
• Language: English
• Published: United States 01-04-2024
• Subjects: Antihypertensive Agents - pharmacology; Antihypertensive Agents - therapeutic use; Blood Pressure; Calcium Channel Blockers - pharmacology; Calcium Channel Blockers - therapeutic use; Humans; Hypertension - diagnosis; Hypertension - drug therapy; Hypertension - epidemiology; Renal Dialysis - adverse effects; White Coat Hypertension
• ISSN: 1533-3450
• DOI: 10.1681/ASN.0000000000000315

Apparent treatment-resistant hypertension is defined as an elevated BP despite the use of ≥3 antihypertensive medications from different classes or the use of ≥4 antihypertensives regardless of BP levels. Among patients receiving maintenance hemodialysis or peritoneal dialysis, using this definition, the prevalence of apparent treatment-resistant hypertension is estimated to be between 18% and 42%. Owing to the lack of a rigorous assessment of some common causes of pseudoresistance, the burden of true resistant hypertension in the dialysis population remains unknown. What distinguishes apparent treatment-resistance from true resistance is white-coat hypertension and adherence to medications. Accordingly, the diagnostic workup of a dialysis patient with apparent treatment-resistant hypertension on dialysis includes the accurate determination of BP control status with the use of home or ambulatory BP monitoring and exclusion of nonadherence to the prescribed antihypertensive regimen. In a patient on dialysis with inadequately controlled BP, despite adherence to therapy with maximally tolerated doses of a β -blocker, a long-acting dihydropyridine calcium channel blocker, and a renin-angiotensin system inhibitor, volume-mediated hypertension is the most important treatable cause of resistance. In daily clinical practice, such patients are often managed with intensification of antihypertensive therapy. However, this therapeutic strategy is likely to fail if volume overload is not adequately recognized or treated. Instead of increasing the number of prescribed BP-lowering medications, we recommend diet and dialysate restricted in sodium to facilitate achievement of dry weight. The achievement of dry weight is facilitated by an adequate time on dialysis of at least 4 hours for delivering an adequate dialysis dose. In this article, we review the epidemiology, diagnosis, and management of resistant hypertension among patients on dialysis.